1. Wang, Tao, Liu, Yufeng, Li, Qing, Liu, Dawei, Li, Bin. 2022. Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma. In Frontiers in immunology, 13, 999823. doi:10.3389/fimmu.2022.999823. https://pubmed.ncbi.nlm.nih.gov/36225932/
2. Xu, Jiahao, Hu, Zhengang, Cao, Hui, Cheng, Quan, Li, Jingbo. 2022. Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma. In Frontiers in immunology, 13, 981764. doi:10.3389/fimmu.2022.981764. https://pubmed.ncbi.nlm.nih.gov/36605188/
3. Chen, Gaoxiang, Zhang, Jianan, Teng, Weifeng, Luo, Yong, Ji, Xiaochun. 2023. FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis. In Heliyon, 9, e18655. doi:10.1016/j.heliyon.2023.e18655. https://pubmed.ncbi.nlm.nih.gov/37554785/
4. Lu, Hanwen, Zhou, Liwei, Zhang, Bingchang, Yang, Huiyin, Wang, Zhanxiang. 2022. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma. In Frontiers in medicine, 9, 939776. doi:10.3389/fmed.2022.939776. https://pubmed.ncbi.nlm.nih.gov/36523779/
5. Dreishpoon, Margaret B, Bick, Nolan R, Petrova, Boryana, Golub, Todd R, Tsvetkov, Peter. 2023. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. In The Journal of biological chemistry, 299, 105046. doi:10.1016/j.jbc.2023.105046. https://pubmed.ncbi.nlm.nih.gov/37453661/
6. Sun, Bo, Ding, Peng, Song, Yinghui, Peng, Chuang, Liu, Sulai. 2024. FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. In Redox biology, 75, 103302. doi:10.1016/j.redox.2024.103302. https://pubmed.ncbi.nlm.nih.gov/39128228/
智鼠故事 
